184 related articles for article (PubMed ID: 31449183)
21. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors.
Kim EY; Roshanravan H; Dryer SE
Biochim Biophys Acta Mol Basis Dis; 2017 Sep; 1863(9):2342-2354. PubMed ID: 28629718
[TBL] [Abstract][Full Text] [Related]
22. c-Src is in the effector pathway linking uPAR and podocyte injury.
Kopp JB; Heymann J
J Clin Invest; 2019 Apr; 129(5):1827-1829. PubMed ID: 30939121
[TBL] [Abstract][Full Text] [Related]
23. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease.
Yoo TH; Pedigo CE; Guzman J; Correa-Medina M; Wei C; Villarreal R; Mitrofanova A; Leclercq F; Faul C; Li J; Kretzler M; Nelson RG; Lehto M; Forsblom C; Groop PH; Reiser J; Burke GW; Fornoni A; Merscher S
J Am Soc Nephrol; 2015 Jan; 26(1):133-47. PubMed ID: 24925721
[TBL] [Abstract][Full Text] [Related]
24. Podocyte injury-driven intracapillary plasminogen activator inhibitor type 1 accelerates podocyte loss via uPAR-mediated β1-integrin endocytosis.
Kobayashi N; Ueno T; Ohashi K; Yamashita H; Takahashi Y; Sakamoto K; Manabe S; Hara S; Takashima Y; Dan T; Pastan I; Miyata T; Kurihara H; Matsusaka T; Reiser J; Nagata M
Am J Physiol Renal Physiol; 2015 Mar; 308(6):F614-26. PubMed ID: 25587125
[TBL] [Abstract][Full Text] [Related]
25. Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.
Jin J; Li YW; He Q
Transplant Proc; 2015; 47(6):1760-5. PubMed ID: 26293047
[TBL] [Abstract][Full Text] [Related]
26. The pathogenesis of focal segmental glomerulosclerosis.
Jefferson JA; Shankland SJ
Adv Chronic Kidney Dis; 2014 Sep; 21(5):408-16. PubMed ID: 25168829
[TBL] [Abstract][Full Text] [Related]
27. Monitoring suPAR levels in post-kidney transplant focal segmental glomerulosclerosis treated with therapeutic plasma exchange and rituximab.
Alachkar N; Li J; Matar D; Vujjini V; Alasfar S; Tracy M; Reiser J; Wei C
BMC Nephrol; 2018 Dec; 19(1):361. PubMed ID: 30558559
[TBL] [Abstract][Full Text] [Related]
28. Permeability factors in focal and segmental glomerulosclerosis.
Reiser J; Nast CC; Alachkar N
Adv Chronic Kidney Dis; 2014 Sep; 21(5):417-21. PubMed ID: 25168830
[TBL] [Abstract][Full Text] [Related]
29. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury.
Zhang B; Shi W; Ma J; Sloan A; Faul C; Wei C; Reiser J; Yang Y; Liu S; Wang W
J Mol Med (Berl); 2012 Dec; 90(12):1407-20. PubMed ID: 23015147
[TBL] [Abstract][Full Text] [Related]
30. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.
Hahm E; Wei C; Fernandez I; Li J; Tardi NJ; Tracy M; Wadhwani S; Cao Y; Peev V; Zloza A; Lusciks J; Hayek SS; O'Connor C; Bitzer M; Gupta V; Sever S; Sykes DB; Scadden DT; Reiser J
Nat Med; 2017 Jan; 23(1):100-106. PubMed ID: 27941791
[TBL] [Abstract][Full Text] [Related]
31. Urokinase, urokinase receptor, and plasminogen activator inhibitor-1 expression on podocytes in immunoglobulin A glomerulonephritis.
Lee JH; Oh MH; Park JS; Na GJ; Gil HW; Yang JO; Lee EY; Hong SY
Korean J Intern Med; 2014 Mar; 29(2):176-82. PubMed ID: 24648800
[TBL] [Abstract][Full Text] [Related]
32. Circulating permeability factor suPAR: from concept to discovery to clinic.
Reiser J
Trans Am Clin Climatol Assoc; 2013; 124():133-8. PubMed ID: 23874017
[TBL] [Abstract][Full Text] [Related]
33. Salvianolic acid A attenuates steroid resistant nephrotic syndrome through suPAR/uPAR-αvβ3 signaling Inhibition.
Li X; Qi D; Wang MY; Ji K; Xie QL; Wang Y; Du SH; Fan HY
J Ethnopharmacol; 2021 Oct; 279():114351. PubMed ID: 34157324
[TBL] [Abstract][Full Text] [Related]
34. Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification.
Morath C; Wei C; Macher-Goeppinger S; Schwenger V; Zeier M; Reiser J
Am J Ther; 2013; 20(2):226-9. PubMed ID: 23466622
[TBL] [Abstract][Full Text] [Related]
35. Protein A immunoadsorption cannot significantly remove the soluble receptor of urokinase from sera of patients with recurrent focal segmental glomerulosclerosis.
Beaudreuil S; Zhang X; Kriaa F; Dantal J; Francois H; Vazquez A; Charpentier B; Lorenzo HK; Durrbach A
Nephrol Dial Transplant; 2014 Feb; 29(2):458-63. PubMed ID: 24235085
[TBL] [Abstract][Full Text] [Related]
36. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.
Bock ME; Price HE; Gallon L; Langman CB
Clin J Am Soc Nephrol; 2013 Aug; 8(8):1304-11. PubMed ID: 23620441
[TBL] [Abstract][Full Text] [Related]
37. [Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].
Segarra A; Jatem E; Quiles MT; Arbós MA; Ostos H; Valtierra N; Carnicer C; Salcedo MT
Nefrologia; 2014; 34(1):53-61. PubMed ID: 24463863
[TBL] [Abstract][Full Text] [Related]
38. Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infection.
Outinen TK; Mäkelä S; Huttunen R; Mäenpää N; Libraty D; Vaheri A; Mustonen J; Aittoniemi J
J Intern Med; 2014 Oct; 276(4):387-95. PubMed ID: 24717117
[TBL] [Abstract][Full Text] [Related]
39. Soluble Urokinase Receptor and Acute Kidney Injury.
Hayek SS; Leaf DE; Samman Tahhan A; Raad M; Sharma S; Waikar SS; Sever S; Camacho A; Wang X; Dande RR; Ibrahim NE; Baron RM; Altintas MM; Wei C; Sheikh-Hamad D; Pan JS; Holliday MW; Januzzi JL; Weisbord SD; Quyyumi AA; Reiser J
N Engl J Med; 2020 Jan; 382(5):416-426. PubMed ID: 31995687
[TBL] [Abstract][Full Text] [Related]
40. Soluble urokinase receptor and focal segmental glomerulosclerosis.
Reiser J; Wei C; Tumlin J
Curr Opin Nephrol Hypertens; 2012 Jul; 21(4):428-32. PubMed ID: 22569341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
